Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy

Biochemical Pharmacology(2021)10.1016/j.bcp.2021.114666Source: DataRank Database

Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy is a research paper published in Biochemical Pharmacology (2021). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 1.79)OA: hybridTopics (65)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (29)

Paula Martínez-Román,Sara Rodríguez-Mora ORCID,Montserrat Torres ORCID,María C. Puertas ORCID,Elena Mateos ORCID

Live enrichment

PubMed:34186065 PMC:PMC8478809 OpenAlex:https://openalex.org/W3174900047

National Institutes of Health

Grant: R01AI143567

Ministerio de Ciencia e Innovación

Grant: RD16CIII/0002/0001

European Regional Development Fund

Grant: FIS PI16CIII/00034-ISCIII-FEDER

Gobierno de España Ministerio de Ciencia e Innovación

Grant: PID2019-110275RB-I00

National Institutes of Health

Grant: 5R01AI143567-03

Tyrosine Kinase inhibition: The New Front in HIV Cure Efforts

Instituto de Salud Carlos III

FWCI

1.79

Citation Percentile

0.8%

Influential Citations

Citation Trend

2021

2022

2023

2024

2025

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.bcp.2021.114666

HYBRIDhttps://doi.org/10.1016/j.bcp.2021.114666

publisherhttps://doi.org/10.1016/j.bcp.2021.114666

publisherhttps://api.elsevier.com/content/article/PII:S0006295221002793?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0006295221002793?httpAccept=text/plain

Fields of Study

HIV Research and TreatmentHIV/AIDS drug development and treatmentImmune Cell Function and InteractionMedicine0301 basic medicine03 medical and health sciences0303 health sciences

MeSH Terms

DasatinibReinfectionAdultCross-Sectional StudiesDrug Therapy, CombinationFemaleHumansMaleMiddle AgedProvirusesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHIV-1HIV InfectionsTreatment OutcomeAnti-Retroviral AgentsProtein Kinase Inhibitors

Keywords

DasatinibViremiaImmunologySAMHD1MedicineVirologyProvirusPeripheral blood mononuclear cellViral loadRegimenVirusBiologyMyeloid leukemiaInternal medicineReverse transcriptaseIn vitroImatinibCd4+ T CellsHiv ReservoirHiv Functional CureProviral ReactivationAdultMaleLeucèmia mieloideHIV InfectionsCD4+T cellsProvirusesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveVIH (Virus)HumansProtein Kinase InhibitorsHIV (Viruses)AntiretroviralsMiddle AgedAntiretroviral agentsCross-Sectional StudiesTreatment OutcomeAnti-Retroviral AgentsReinfectionHIV-1Drug Therapy, CombinationFemale

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy

FAIR Checklist

Authors (29)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)